A Phase IIa (proof of concept), randomized, double blind, placebo controlled, multicenter clinical trial to evaluate the safety and efficacy of oral treatment with PBF-677 in patients with mild to moderate ulcerative colitis.
Phase of Trial: Phase II
Latest Information Update: 19 Dec 2018
At a glance
- Drugs PBF 677 (Primary) ; Mesalazine
- Indications Ulcerative colitis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Palobiofarma
- 14 Jun 2018 Status changed from planning to recruiting.
- 13 Apr 2018 New trial record
- 12 Apr 2018 According to a Palobiofarma media release, the company is planning to start this trial in the second quarter of 2018.